Is NKTR or NRIX more undervalued in 2026?

CirclFi compares Nektar Therapeutics (NKTR) and Nurix Therapeutics, Inc. (NRIX) using 13 institutional-grade valuation models. NKTR has a Quality of Company score of 5.9/10 while NRIX scores 6.4/10.

Which is a better buy — NKTR or NRIX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do NKTR and NRIX valuations compare?

NKTR at $65.01 and NRIX at $17.67 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

NKTR vs NRIX Valuation Comparison 2026 — Intrinsic Value Analysis

NKTR

Biotechnology

Nektar Therapeutics

Quality

5.9

out of 10

Value Trap

SAFE

Price

$65.01

Last close

Models

12/13

Active

NRIX

Biotechnology

Nurix Therapeutics, Inc.

Quality

6.4

out of 10

Value Trap

SAFE

Price

$17.67

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	NKTR Fair Value	NKTR Upside	NRIX Fair Value	NRIX Upside
Bayesian DCF	Intrinsic	$18.82	-71.1%	$4.91	-72.2%
Earnings Power Value	Intrinsic	$5.62	-93.5%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$9.48	-85.4%	$4.75	-73.1%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for NKTR vs NRIX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NKTR vs NRIX — Which Stock Is More Undervalued?

NRIX scores higher with a 6.4/10 quality rating vs NKTR's 5.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Nektar Therapeutics (NKTR) and Nurix Therapeutics, Inc. (NRIX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NKTR currently trades at $65.01 with a QOC of 5.9/10, while NRIX trades at $17.67 with a QOC of 6.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).